Tenofovir plasma concentration from preexposure prophylaxis at the time of potential HIV exposure: A population pharmacokinetic modeling and simulation study involving serodiscordant couples in east Africa

Surulivelrajan Mallayasamy, Ayyappa Chaturvedula, Michael J. Fossler, Mark Sale, Vineet Goti, Namandje N. Bumpus, Mark A. Marzinke, Craig W. Hendrix, Jessica E. Haberer

Research output: Contribution to journalArticle

Abstract

The Partners Demonstration Project was a prospective, open-label, implementation science-driven study of preexposure prophylaxis (PrEP) among heterosexual HIV serodiscordant couples in Kenya and Uganda. Adherence data were collected using the Medication Event Monitoring System (MEMS), and time of sexual activity was collected using the mobile phone short message service (SMS). Two plasma samples were collected at a single study visit. We integrated adherence, pharmacokinetics, and SMS data using a population pharmacokinetic (PopPK) model to simulate tenofovir plasma concentrations from PrEP at the time of sexual activity. In the first stage of this analysis, we used data from the current study to update a prior PopPK model of tenofovir (TFV) developed with data from the Partners PrEP Study (a phase III clinical trial). The second stage involved simulating plasma concentrations at the time of sexual activity using empirical Bayes estimates (EBEs) derived from the final model. In addition, EBEs from a previously published parent metabolite model of TFV (MTN-001, an open-label 3-way crossover study in healthy women) was used to simulate tenofovir diphosphate (TFV-DP) concentrations. We estimated percent PrEP "coverage" as the number of reported sexual events during which simulated concentrations were above an a priori threshold concentrations associated with a high degree of protection from HIV infection: Plasma TFV of >40 ng/ml and peripheral blood mononuclear cell (PBMC) TFV-DP concentration of >36 fmol/million cells. The levels of coverage were 72% for TFV and 81% for TFV-DP. These levels are consistent with a high degree of protection against HIV acquisition in this study of a pragmatic delivery model for antiretroviral-based HIV prevention.

Original languageEnglish
Article numbere00446-19
JournalAntimicrobial agents and chemotherapy
Volume63
Issue number8
DOIs
StatePublished - 1 Jan 2019

Fingerprint

Tenofovir
Eastern Africa
Pharmacokinetics
HIV
Population
Sexual Behavior
Text Messaging
Phase III Clinical Trials
Cell Phones
Uganda
Kenya
Heterosexuality
Cross-Over Studies
HIV Infections
Blood Cells

Keywords

  • Population pharmacokinetics
  • PrEP
  • Preexposure prophylaxis
  • Tenofovir

Cite this

Mallayasamy, Surulivelrajan ; Chaturvedula, Ayyappa ; Fossler, Michael J. ; Sale, Mark ; Goti, Vineet ; Bumpus, Namandje N. ; Marzinke, Mark A. ; Hendrix, Craig W. ; Haberer, Jessica E. / Tenofovir plasma concentration from preexposure prophylaxis at the time of potential HIV exposure : A population pharmacokinetic modeling and simulation study involving serodiscordant couples in east Africa. In: Antimicrobial agents and chemotherapy. 2019 ; Vol. 63, No. 8.
@article{fe6481f4bb134fab809507158a3ba435,
title = "Tenofovir plasma concentration from preexposure prophylaxis at the time of potential HIV exposure: A population pharmacokinetic modeling and simulation study involving serodiscordant couples in east Africa",
abstract = "The Partners Demonstration Project was a prospective, open-label, implementation science-driven study of preexposure prophylaxis (PrEP) among heterosexual HIV serodiscordant couples in Kenya and Uganda. Adherence data were collected using the Medication Event Monitoring System (MEMS), and time of sexual activity was collected using the mobile phone short message service (SMS). Two plasma samples were collected at a single study visit. We integrated adherence, pharmacokinetics, and SMS data using a population pharmacokinetic (PopPK) model to simulate tenofovir plasma concentrations from PrEP at the time of sexual activity. In the first stage of this analysis, we used data from the current study to update a prior PopPK model of tenofovir (TFV) developed with data from the Partners PrEP Study (a phase III clinical trial). The second stage involved simulating plasma concentrations at the time of sexual activity using empirical Bayes estimates (EBEs) derived from the final model. In addition, EBEs from a previously published parent metabolite model of TFV (MTN-001, an open-label 3-way crossover study in healthy women) was used to simulate tenofovir diphosphate (TFV-DP) concentrations. We estimated percent PrEP {"}coverage{"} as the number of reported sexual events during which simulated concentrations were above an a priori threshold concentrations associated with a high degree of protection from HIV infection: Plasma TFV of >40 ng/ml and peripheral blood mononuclear cell (PBMC) TFV-DP concentration of >36 fmol/million cells. The levels of coverage were 72{\%} for TFV and 81{\%} for TFV-DP. These levels are consistent with a high degree of protection against HIV acquisition in this study of a pragmatic delivery model for antiretroviral-based HIV prevention.",
keywords = "Population pharmacokinetics, PrEP, Preexposure prophylaxis, Tenofovir",
author = "Surulivelrajan Mallayasamy and Ayyappa Chaturvedula and Fossler, {Michael J.} and Mark Sale and Vineet Goti and Bumpus, {Namandje N.} and Marzinke, {Mark A.} and Hendrix, {Craig W.} and Haberer, {Jessica E.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1128/AAC.00446-19",
language = "English",
volume = "63",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "8",

}

Tenofovir plasma concentration from preexposure prophylaxis at the time of potential HIV exposure : A population pharmacokinetic modeling and simulation study involving serodiscordant couples in east Africa. / Mallayasamy, Surulivelrajan; Chaturvedula, Ayyappa; Fossler, Michael J.; Sale, Mark; Goti, Vineet; Bumpus, Namandje N.; Marzinke, Mark A.; Hendrix, Craig W.; Haberer, Jessica E.

In: Antimicrobial agents and chemotherapy, Vol. 63, No. 8, e00446-19, 01.01.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Tenofovir plasma concentration from preexposure prophylaxis at the time of potential HIV exposure

T2 - A population pharmacokinetic modeling and simulation study involving serodiscordant couples in east Africa

AU - Mallayasamy, Surulivelrajan

AU - Chaturvedula, Ayyappa

AU - Fossler, Michael J.

AU - Sale, Mark

AU - Goti, Vineet

AU - Bumpus, Namandje N.

AU - Marzinke, Mark A.

AU - Hendrix, Craig W.

AU - Haberer, Jessica E.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The Partners Demonstration Project was a prospective, open-label, implementation science-driven study of preexposure prophylaxis (PrEP) among heterosexual HIV serodiscordant couples in Kenya and Uganda. Adherence data were collected using the Medication Event Monitoring System (MEMS), and time of sexual activity was collected using the mobile phone short message service (SMS). Two plasma samples were collected at a single study visit. We integrated adherence, pharmacokinetics, and SMS data using a population pharmacokinetic (PopPK) model to simulate tenofovir plasma concentrations from PrEP at the time of sexual activity. In the first stage of this analysis, we used data from the current study to update a prior PopPK model of tenofovir (TFV) developed with data from the Partners PrEP Study (a phase III clinical trial). The second stage involved simulating plasma concentrations at the time of sexual activity using empirical Bayes estimates (EBEs) derived from the final model. In addition, EBEs from a previously published parent metabolite model of TFV (MTN-001, an open-label 3-way crossover study in healthy women) was used to simulate tenofovir diphosphate (TFV-DP) concentrations. We estimated percent PrEP "coverage" as the number of reported sexual events during which simulated concentrations were above an a priori threshold concentrations associated with a high degree of protection from HIV infection: Plasma TFV of >40 ng/ml and peripheral blood mononuclear cell (PBMC) TFV-DP concentration of >36 fmol/million cells. The levels of coverage were 72% for TFV and 81% for TFV-DP. These levels are consistent with a high degree of protection against HIV acquisition in this study of a pragmatic delivery model for antiretroviral-based HIV prevention.

AB - The Partners Demonstration Project was a prospective, open-label, implementation science-driven study of preexposure prophylaxis (PrEP) among heterosexual HIV serodiscordant couples in Kenya and Uganda. Adherence data were collected using the Medication Event Monitoring System (MEMS), and time of sexual activity was collected using the mobile phone short message service (SMS). Two plasma samples were collected at a single study visit. We integrated adherence, pharmacokinetics, and SMS data using a population pharmacokinetic (PopPK) model to simulate tenofovir plasma concentrations from PrEP at the time of sexual activity. In the first stage of this analysis, we used data from the current study to update a prior PopPK model of tenofovir (TFV) developed with data from the Partners PrEP Study (a phase III clinical trial). The second stage involved simulating plasma concentrations at the time of sexual activity using empirical Bayes estimates (EBEs) derived from the final model. In addition, EBEs from a previously published parent metabolite model of TFV (MTN-001, an open-label 3-way crossover study in healthy women) was used to simulate tenofovir diphosphate (TFV-DP) concentrations. We estimated percent PrEP "coverage" as the number of reported sexual events during which simulated concentrations were above an a priori threshold concentrations associated with a high degree of protection from HIV infection: Plasma TFV of >40 ng/ml and peripheral blood mononuclear cell (PBMC) TFV-DP concentration of >36 fmol/million cells. The levels of coverage were 72% for TFV and 81% for TFV-DP. These levels are consistent with a high degree of protection against HIV acquisition in this study of a pragmatic delivery model for antiretroviral-based HIV prevention.

KW - Population pharmacokinetics

KW - PrEP

KW - Preexposure prophylaxis

KW - Tenofovir

UR - http://www.scopus.com/inward/record.url?scp=85070658182&partnerID=8YFLogxK

U2 - 10.1128/AAC.00446-19

DO - 10.1128/AAC.00446-19

M3 - Article

C2 - 31182536

AN - SCOPUS:85070658182

VL - 63

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 8

M1 - e00446-19

ER -